Your browser doesn't support javascript.
loading
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt, Andrew; Papp, Kim A; Merola, Joseph F; Gottlieb, Alice B; Cross, Nancy; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Griffiths, Christopher E M.
Afiliação
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.
  • Papp KA; Probity Medical Research and K. Papp Clinical Research, Waterloo, and University of Toronto, Toronto, Ontario.
  • Merola JF; Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gottlieb AB; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Cross N; UCB Biosciences Inc, Raleigh, North Carolina.
  • Madden C; UCB Biosciences Inc, Raleigh, North Carolina.
  • Wang M; UCB Biosciences Inc, Raleigh, North Carolina.
  • Cioffi C; UCB Pharma, Brussels, Belgium.
  • Griffiths CEM; Salford Royal Hospital, University of Manchester, Manchester NIHR Biomedical Research Centre, Manchester, United Kingdom.
J Am Acad Dermatol ; 83(5): 1367-1374, 2020 Nov.
Article em En | MEDLINE | ID: mdl-32473974

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2020 Tipo de documento: Article